Schmidt, Julie AFensom, Georgina KRinaldi, SabinaScalbert, AugustinAppleby, Paul NAchaintre, DavidGicquiau, AudreyGunter, Marc JFerrari, PietroKaaks, RudolfKühn, TilmanFloegel, AnnaBoeing, HeinerTrichopoulou, AntoniaLagiou, PagonaAnifantis, EleutheriosAgnoli, ClaudiaPalli, DomenicoTrevisan, MorenaTumino, RosarioBueno-de-Mesquita, H BasAgudo, AntonioLarrañaga, NereaRedondo-Sánchez, DanielBarricarte, AurelioHuerta, José MariaQuirós, J RamónWareham, NickKhaw, Kay-TeePerez-Cornago, AuroraJohansson, MattiasCross, Amanda JTsilidis, Konstantinos KRiboli, ElioKey, Timothy JTravis, Ruth C2023-01-252023-01-252017-07-05http://hdl.handle.net/10668/11372Little is known about how pre-diagnostic metabolites in blood relate to risk of prostate cancer. We aimed to investigate the prospective association between plasma metabolite concentrations and risk of prostate cancer overall, and by time to diagnosis and tumour characteristics, and risk of death from prostate cancer. In a case-control study nested in the European Prospective Investigation into Cancer and Nutrition, pre-diagnostic plasma concentrations of 122 metabolites (including acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexose and sphingolipids) were measured using targeted mass spectrometry (AbsoluteIDQ p180 Kit) and compared between 1077 prostate cancer cases and 1077 matched controls. Risk of prostate cancer associated with metabolite concentrations was estimated by multi-variable conditional logistic regression, and multiple testing was accounted for by using a false discovery rate controlling procedure. Seven metabolite concentrations, i.e. acylcarnitine C18:1, amino acids citrulline and trans-4-hydroxyproline, glycerophospholipids PC aa C28:1, PC ae C30:0 and PC ae C30:2, and sphingolipid SM (OH) C14:1, were associated with prostate cancer (p  Several metabolites, i.e. C18:1, citrulline, trans-4-hydroxyproline, three glycerophospholipids and SM (OH) C14:1, might be related to prostate cancer. Analyses by time to diagnosis indicated that citrulline may be a marker of subclinical prostate cancer, while other metabolites might be related to aetiology. Several glycerophospholipids were inversely related to advanced stage disease. More prospective data are needed to confirm these associations.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AcylcarnitinesAmino acidsBiogenic aminesEuropean Prospective Investigation into Cancer and Nutrition (EPIC)GlycerophospholipidsHexoseMass spectrometryMetabolomicsProspective studyProstate cancer riskSphingolipidsAgedBiomarkersCase-Control StudiesCohort StudiesFollow-Up StudiesHumansLogistic ModelsMaleMass SpectrometryMiddle AgedNutritional StatusOdds RatioProspective StudiesProstatic Neoplasmsresearch article28676103open access10.1186/s12916-017-0885-61741-7015PMC5497352https://doi.org/10.1186/s12916-017-0885-6https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497352/pdf